ONCOBIOME
Dead / Abandoned — Abandoned — express abandonment (as of 02 Oct 2017)
What this means for you
This application is over — abandoned 21 Sept 2017. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 86300247
- Mark type
- Stylized text
- Filed
- 04 Jun 2014
- Abandoned
- 21 Sept 2017
- Attorney of record
- Heather E Balmat
Goods and services
- Class 005 — Pharmaceuticals: microbial preparations for pharmaceutical, veterinary and medical purposes, namely, microbial preparations for use as tumor suppressing agents, immuno-suppressing agents, immuno-stimulating agents, and anti-cancer agents; dietary supplements, nutritional supplements, nutraceuticals for use as dietary supplements, food supplements, nutritionally fortified vegetable-based food, beverages, and nutritional food bars, all of the foregoing containing microorganisms for medical, therapeutic, or preventative purposes; therapeutic pharmaceuticals containing microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; therapeutic pharmaceuticals containing derivatives of microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; pharmaceutical, veterinary and medical preparations and substances, namely, anti-microbial preparations and substances, anti-bacterial, anti-fungal, anti-viral, and anti-protist preparations and substances, all for the treatment of cancer, cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; anti-cancer preparations and substances; preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, namely, combination preparations containing in majority part antimicrobial preparations and lesser amounts of microbial preparations and anti-cancer preparations for use as a preservative; pharmaceutical preparations and substances for the treatment of cancer, namely, microbial and anti-microbial preparations for veterinary and medical use; anti-cancer preparations for use in treating cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; pharmaceutical preparations for the treatment of infectious diseases and cancer, namely, combination preparations of anti-cancer agents, microbial preparations and anti-microbial preparations; diagnostic kits for diagnosing disease, determination of likelihood of disease, prognosis of responsiveness to therapy and/or patient prognosis comprised of diagnostic reagents and buffers for the detection of microbes, viral, bacterial, fungal, and parasitic or non-parasitic protist infections, inflammation, and biomarkers associated with pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases; preparations for detecting mutations in genes for medical purposes as used in the collection of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic medical data and related clinical data
- Class 009 — Scientific and electric apparatus: scientific, analytical, and statistical computer software for creating and managing databases containing genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data derived from patient clinical care information and medical research data; computer software for analyzing and creating statistical models derived from patient clinical care information and medical research data in the nature of genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data
- Class 010 — Medical apparatus: medical diagnostic instruments for screening, assessing, and determining appropriate courses of treatment in relation to pre-neoplastic lesions, neoplasms, tumors, cancers and metastases
- Class 042 — Scientific and technological services: electronic data storage services, namely, electronic storage of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data and related clinical data for treatment and diagnostic purposes; database, computer-readable program and software development services, namely, development of scientific, analytical, and statistical software and related databases for use in conjunction with genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data gathered from patient clinical care information and medical research data; scientific, chemical, biochemical and microbiological research; scientific research in the field of genetics and genetic engineering of microbes; scientific research in the field of genetic and molecular tests, including tests for microbial populations in vertebrate samples; research and development of therapeutic pharmaceuticals, consumer medical products, diagnostic equipment and prognostic tools consisting of genetically engineered microorganisms, combinations of microorganisms, and individually selected microorganisms for treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers and metastases
- Class 044 — Medical, beauty and agricultural services: medical clinics; veterinary dentistry; behavioural analysis for medical purposes; genetic testing for medical purposes; collection and preservation of human blood for medical purposes; medical diagnostic testing for assessing pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases
Owner
- EVELO THERAPEUTICS, INC., CAMBRIDGE, MA, US
- VL28, Inc., Cambridge, MA, US
Prosecution history
- 02 Oct 2017 — ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
- 02 Oct 2017 — ABANDONMENT - EXPRESS MAILED
- 21 Sept 2017 — EXPARTE APPEAL TERMINATED
- 21 Sept 2017 — EXPARTE APPEAL DISMISSED AS MOOT
- 21 Jul 2017 — NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
- 21 Jul 2017 — ACTION DENYING REQ FOR RECON E-MAILED
- 21 Jul 2017 — ACTION CONTINUING FINAL - COMPLETED
- 03 Jul 2017 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Jul 2017 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Jun 2017 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 29 Jun 2017 — EX PARTE APPEAL-INSTITUTED
- 29 Jun 2017 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 29 Jun 2017 — EXPARTE APPEAL RECEIVED AT TTAB
- 29 Dec 2016 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 29 Dec 2016 — FINAL REFUSAL E-MAILED